Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 16;192(10):4685–4696. doi: 10.4049/jimmunol.1302253

Table I.

Sequence variation for all tested HLA-B*57-restricted epitopes and variants in the HIV-1 Gag p24- and Nef-region for all subjects.

graphic file with name nihms576809f7.jpg

HXB2 is used as the reference sequence for the HLA-B*57-restricted epitopes in Gag p24 (ISW9, KF11, TW10 and QW9) and Nef (KL10, HQ10 and YT9).

a

Patient identity.

b

Weeks post infection; sequences and immunological data were obtained from plasma and PBMC samples respectively, from the same time point in the majority of the patients. Wpi in parenthesis are PBMC samples taken at a different time point compared to the plasma samples.

c

The number of sequenced single nef genomes are indicated after each sequence

d

HRPs (P1–P3): high-risk progressors; LRPs (P4–P6): low-risk progressors. The epitopes corresponding to the major viral population at each time point are marked in boldface. Two epitopes marked in boldface at the same time point correspond to a 50–50 proportion of the respective variants. The epitopes with a positive CD8+ T cell response are filled in gray.

e

Sequence data for the Nef-region was not obtained for all time points.